ARTIVA BIOTHERAPEUTICS INC Stock Price, News & Analysis

Artiva (Nasdaq: ARTV) reported third-quarter 2025 results and clinical updates for AlloNK (AB-101). Key highlights include FDA Fast Track designation in October 2025 for AlloNK in refractory rheumatoid arthritis (RA) with rituximab, and >100 patients treated across oncology and autoimmune indications. The company reported $123.0 million in cash, cash equivalents, and investments as of September 30, 2025, with a runway into Q2 2027. Initial clinical response data from >15 refractory RA patients are expected in 1H 2026, and FDA discussions on pivotal trial design are planned for 1H 2026.

Financials: R&D expense was $17.6M vs $13.5M prior year; G&A was $5.3M vs $4.8M; other income, net $1.4M vs $0.9M; net loss $21.5M vs $17.5M. CFO transition announced, with leadership change effective end of December 2025.

Artiva Biotherapeutics (Nasdaq: ARTV) will host a virtual webcast on November 12, 2025 at 8 a.m. ET to discuss initial safety and translational data for AlloNK® plus anti-CD20 antibodies in autoimmune disease.

Key disclosed items: initial safety data in 32 patients reporting a favorable tolerability profile and outpatient feasibility; translational results showing uniform, deep B-cell depletion; a high-sensitivity B-cell assay with 10- to 50-fold greater sensitivity; and characterisation of the unmet need in refractory rheumatoid arthritis. A live Q&A and replay will be available via the company website.

Artiva Biotherapeutics (Nasdaq: ARTV) announced that management will participate in investor conferences in November 2025 and will offer live webcasts and replays.

Key events: a fireside chat at TD Cowen's Immunology & Inflammation Summit (Virtual) on Wednesday, November 12, 2025 at 11:30 a.m. ET, and a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 12:00 p.m. GMT. Management is available for investor meetings for registered attendees. Live webcasts will be accessible via the Investors section on Artivabio.com, with replay available for 90 days after each event.

Artiva Biotherapeutics (Nasdaq: ARTV) prioritized refractory rheumatoid arthritis (RA) as the lead indication for AlloNK (AB-101) and announced that the U.S. FDA granted Fast Track Designation for AlloNK in refractory RA in combination with rituximab. The company reported >20 patients treated with AlloNK plus monoclonal antibody therapy at 1 billion and 4 billion cell doses across multiple autoimmune indications.

Emerging translational and safety data are expected in mid-November; clinical response data from >15 refractory RA patients are expected in 1H 2026. FDA interactions are planned in 1H 2026 to discuss a potential pivotal trial.

Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotech company focused on cell therapies for autoimmune diseases and cancers, will participate in the Cantor Global Healthcare Conference 2025. The company's management will engage in a fireside chat on September 3, 2025, at 9:45 a.m. EDT.

The presentation will be accessible through a live webcast in the "Investors" section of Artivabio.com, with the replay available for 90 days after the event. Management will also be available for meetings with registered conference attendees.

Artiva Biotherapeutics (NASDAQ:ARTV) has reported significant progress in its clinical trials for AlloNK® therapy in autoimmune diseases during Q2 2025. The company has treated over a dozen patients across multiple sites, with the first patient receiving AlloNK + rituximab in their global Phase 2a basket trial for various autoimmune conditions.

The company ended Q2 2025 with $142.4 million in cash and investments, providing runway into Q2 2027. Financial results showed R&D expenses of $17.9 million and a net loss of $21.3 million. Artiva plans to present initial safety and translational data by year-end 2025, along with announcing their lead indication, followed by clinical response data in 1H2026.

ArrePath (NASDAQ:CTNM) has announced the successful completion of a new financing round led by Boehringer Ingelheim Venture Fund, with participation from existing investors Insight Partners, Innospark, Nor'easter Ventures, and new investor AB Magnitude. The funding, combined with non-dilutive awards from PACE and CARB-X, will support the advancement of their lead program AP-001 and expand their antimicrobial compound development.

Additionally, the company has appointed Dr. Diego Miralles as the new Chair of the Board of Directors. Dr. Miralles brings extensive biotech and pharmaceutical industry experience, having served as CEO of multiple companies including AZURNA Therapeutics, Laronde, and Vividion Therapeutics, and held senior positions at Johnson & Johnson.

Artiva Biotherapeutics (NASDAQ: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat on June 4, 2025, at 9:20 a.m. EDT. The presentation will be accessible via live webcast through the company's investor relations website, with a replay available for 90 days afterward. Additionally, the management team will be available for meetings with registered conference attendees.

Artiva Biotherapeutics (NASDAQ: ARTV) announced promising longer-term Phase 1/2 data for AlloNK® in combination with rituximab for treating B-cell non-Hodgkin lymphoma (B-NHL). The treatment showed a 64% complete response rate (9/14 patients) in heavily pretreated patients naive to CAR-T therapy. The median duration of response has not been reached and extends beyond 19.4 months, comparable to approved auto-CAR-T therapies. The treatment demonstrated a well-tolerated safety profile with no reported cases of cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease. Common side effects were primarily hematologic, including neutropenia (84%), leukopenia (82%), and lymphopenia (71%). The results suggest potential applications for treating autoimmune diseases through enhanced B-cell depletion in outpatient community settings.